Tocilizumab in severe COVID-19
- PMID: 33224347
- PMCID: PMC7667418
- DOI: 10.5114/aoms.2020.97411
Tocilizumab in severe COVID-19
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42. - PubMed
LinkOut - more resources
Full Text Sources